Department of Dermatology and Venereology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czech Republic

Zobrazit více v PubMed

Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129:311–21. PubMed PMC

Canavan TN, Elmets CA, Cantrell WL, et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17:33–47. PubMed

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–38. PubMed

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–46. PubMed

Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–9. PubMed

Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8:3156–72. PubMed PMC

Farhangian ME, Feldman SROV. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16:285–94. PubMed

Tichy M, Zapletalova J. Experience with systemic treatment of severe forms of psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156:29–40. PubMed

Tichy M, Kopova R, Sternbersky J. First experience with therapy of severe forms of psoriasis with biosimilar infliximab. J Eur Acad Dermatol Venereol. 2016;30:491–3. PubMed